326 related articles for article (PubMed ID: 23467620)
1. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex.
Takeyama M; Nogami K; Sasai K; Furukawa S; Shima M
Thromb Haemost; 2018 May; 118(5):830-841. PubMed ID: 29614522
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII S373L: mutation at P1' site confers thrombin cleavage resistance, causing mild haemophilia A.
Johnson DJ; Pemberton S; Acquila M; Mori PG; Tuddenham EG; O'Brien DP
Thromb Haemost; 1994 Apr; 71(4):428-33. PubMed ID: 8052958
[TBL] [Abstract][Full Text] [Related]
5. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
[TBL] [Abstract][Full Text] [Related]
6. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
[TBL] [Abstract][Full Text] [Related]
7. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
[TBL] [Abstract][Full Text] [Related]
8. Functional characteristics of N8, a new recombinant FVIII.
Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
[TBL] [Abstract][Full Text] [Related]
9. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.
Matsumoto T; Nogami K; Ogiwara K; Shima M
Thromb Haemost; 2012 Feb; 107(2):288-301. PubMed ID: 22234708
[TBL] [Abstract][Full Text] [Related]
10. Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A.
Matsumoto T; Nogami K; Tabuchi Y; Yada K; Ogiwara K; Kurono H; Arai N; Shima M
Haemophilia; 2017 Sep; 23(5):e427-e435. PubMed ID: 28750470
[TBL] [Abstract][Full Text] [Related]
11. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
12. Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays.
Radtke KP; Griffin JH; Riceberg J; Gale AJ
J Thromb Haemost; 2007 Jan; 5(1):102-8. PubMed ID: 17059431
[TBL] [Abstract][Full Text] [Related]
13. Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
Livnat T; Shenkman B; Kenet G; Tamarin I; Gillis S; Varon D; Iijima K; Zivelin A; Salomon O
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):673-9. PubMed ID: 22008904
[TBL] [Abstract][Full Text] [Related]
14. Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R.
Miyashita R; Shinozawa K; Inaba H; Amano K; Kinai E
Int J Hematol; 2022 Oct; 116(4):489-499. PubMed ID: 35590009
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
[TBL] [Abstract][Full Text] [Related]
17. Normalization of factor VIII levels in a patient with mild haemophilia A during a 35-year period.
Mainwaring CJ; Evans J; Chana J; Lewis H
Haemophilia; 2006 Nov; 12(6):668-71. PubMed ID: 17083519
[TBL] [Abstract][Full Text] [Related]
18. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
Lewis SJ; Stephens E; Florou G; Macartney NJ; Hathaway LS; Knipping J; Collins PW
Br J Haematol; 2007 Sep; 138(6):775-82. PubMed ID: 17672884
[TBL] [Abstract][Full Text] [Related]
19. Activation, activity and inactivation of factor VIII in factor VIII products.
Orfeo T; Elsman R; Gissel M; Mann KG; Butenas S
Haemophilia; 2016 May; 22(3):462-73. PubMed ID: 26822998
[TBL] [Abstract][Full Text] [Related]
20. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.
Bassus S; Wegert W; Krause M; Escuriola-Ettinghausen C; Siegemund A; Petros S; Scholz T; Scharrer I; Kreuz W; Engelmann L; Kirchmaier CM
Platelets; 2006 Sep; 17(6):378-84. PubMed ID: 16973498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
